Quantcast
Get breaking news alerts via email

Click here to manage your alerts
AstraZeneca to acquire lung drugs from Almirall
Acquisitions » After rejecting Pfizer takeover, British drugmaker buys drugs for $875 million.
First Published Jul 30 2014 11:26 am • Last Updated Jul 30 2014 11:26 am

London • AstraZeneca, the British drugmaker that fended off a Pfizer takeover attempt, agreed to buy the rights to Almirall’s respiratory medicines for $875 million.

AstraZeneca will make additional payments of as much as $1.22 billion if the drugs meet development and sales goals, the London-based company said in a statement Wednesday. Almirall, based in Barcelona, also will transfer its Sofotec device unit to AstraZeneca.

Join the Discussion
Post a Comment

Adding the Almirall drugs will strengthen AstraZeneca’s respiratory business, which includes Symbicort and Pulmicort, the company said. The deal will be neutral to AstraZeneca’s earnings next year and add to them in 2016, AstraZeneca said.

"Our agreement with Almirall brings strategic and long- term value to AstraZeneca’s strong respiratory franchise, one of our key growth platforms," said Pascal Soriot, chief executive officer of AstraZeneca.

Almirall has a market value of about $2.7 billion. Chairman Jorge Gallardo and First Vice Chairman Antonio Gallardo own about 67 percent of the stock via two holding companies.

As part of the deal, AstraZeneca will acquire Eklira, also called Tudorza Pressair, a treatment for smoking-related diseases such as bronchitis and emphysema, which recorded $112 million in sales in 2013 and made up 12 percent of Almirall’s revenue.

Another lung drug, Ebastel, had revenues of $102 million. Almirall’s respiratory drugs combined for $283 million in sales.

Almirall is applying for U.S. approval to market a combination of Eklira with formoterol, developed with New York-based partner Forest Laboratories Inc. Although the combination is approved in Europe, U.S. regulators asked for additional data. Actavis Plc bought Forest this month.

AstraZeneca rejected Pfizer’s bid of $117 billion in May, saying the company’s pipeline of experimental drugs made it more valuable as a standalone company. In a June interview, Soriot said the company wouldn’t make acquisitions as part of its defense strategy, although he said he would consider small to medium-sized acquisitions.


story continues below
story continues below



Copyright 2014 The Salt Lake Tribune. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Top Reader Comments Read All Comments Post a Comment
Click here to read all comments   Click here to post a comment


About Reader Comments


Reader comments on sltrib.com are the opinions of the writer, not The Salt Lake Tribune. We will delete comments containing obscenities, personal attacks and inappropriate or offensive remarks. Flagrant or repeat violators will be banned. If you see an objectionable comment, please alert us by clicking the arrow on the upper right side of the comment and selecting "Flag comment as inappropriate". If you've recently registered with Disqus or aren't seeing your comments immediately, you may need to verify your email address. To do so, visit disqus.com/account.
See more about comments here.
Staying Connected
Videos
Jobs
Contests and Promotions
  • Search Obituaries
  • Place an Obituary

  • Search Cars
  • Search Homes
  • Search Jobs
  • Search Marketplace
  • Search Legal Notices

  • Other Services
  • Advertise With Us
  • Subscribe to the Newspaper
  • Access your e-Edition
  • Frequently Asked Questions
  • Contact a newsroom staff member
  • Access the Trib Archives
  • Privacy Policy
  • Missing your paper? Need to place your paper on vacation hold? For this and any other subscription related needs, click here or call 801.204.6100.